Multiple Myeloma
US Focus Meeting 2026
📍 Boston, MA
🗓️ August 14 - 15, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Multiple Myeloma Focus Meeting 2026, to be held on August 14 - 15, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Multiple Myeloma research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Multiple Myeloma US Focus Meeting 2026:
NR
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
SK
Shaji Kumar, MD
Mayo Clinic, Rochester, MN
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
freya.symons@md-education.com
Agenda & Faculty
August 14, 2026 | Day 1
Session I: Early-Stage CRC
Moderated by:
NR
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
09:00 AM
Role of Mass Spectrometry in Screening, Diagnosis, and Disease Monitoring
DM
David L. Murray, MD
Mayo Clinic, Rochester, MN
09:15 AM
Can We Replace FISH Panel with Sequencing?
MS
Mehmet K. Samur, MD
Dana-Farber Cancer Institute, Boston, MA
09:30 AM
MRD Monitoring in MM – Current Approaches
NM
Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA
10:15 AM
Case Discussion and Q&A
TBD
Fellow / Junior Faculty
Session II: Management of Precursor Conditions
Moderated by:
NM
Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA
10:50 AM
Monoclonal Gammopathy – Diagnosis and Risk Adapted Approach to Monitoring
Natalie Callander, MD
UW Health, Madison, WI
11:05 AM
Smoldering Multiple Myeloma – Current Approaches to Management
SL
Sagar Lonial, MD
Emory Winship Cancer Institute, Atlanta, GA
11:20 AM
Monoclonal Gammopathies – When Are They of Clinical Significance?
VR
Vincent Rajkumar, MD
Mayo Clinic, Rochester, MN
12:05 PM
Case Discussion and Q&A
TBD
Fellow / Junior Faculty
Session III: Other Plasma Cell Disorders
Moderated by:
SK
Shaji Kumar, MD
Mayo Clinic, Rochester, MN
01:55 PM
Management of Light Chain Amyloidosis
AD
Anita D’Souza, MD
Medical College of Wisconsin, Wauwatosa, WI
02:10 PM
Waldenström Macroglobulinemia
Prashant Kapoor, MD
Mayo Clinic, Rochester, MN
02:55 PM
Case Discussion and Q&A
TBD
Fellow / Junior Faculty
Session IV: Newly Diagnosed Multiple Myeloma
Moderated by:
TM
Tom Martin, MD
UCSF Health, San Francisco, CA
03:30 PM
Integrating T-Cell Redirection Therapy into Newly Diagnosed MM Treatment
Surbhi Sidana, MD
Stanford Medicine, CA
03:45 PM
Does Transplant Have a Role in the Management of Myeloma – Upfront or Later?
Amrita Krishnan, MD
City of Hope, Duarte, CA
04:00 PM
Defining Frailty and Making Treatment Decisions
Ashley Rosko, MD
The Ohio State University Comprehensive Cancer Center, Columbus, OH
04:45 PM
Case Discussion and Q&A
TBD
Fellow / Junior Faculty
August 15, 2026 | Day 2
Session V: Individualizing Therapy in Myeloma – Role of Risk Stratification
Moderated by:
SK
Shaji Kumar, MD
Mayo Clinic, Rochester, MN
09:00 AM
How Do We Adapt Treatment to Baseline
Saad Usmani, MD
Memorial Sloan Kettering Cancer Center, New York, NY
09:15 AM
Integrating Response into Treatment Decisions
LC
Luciano Costa, MD
UAB Medicine, Birmingham, AL
09:30 AM
Management of Extramedullary Decisions
Wilson Gonsalves, MD
Mayo Clinic, Rochester, MN
10:15 AM
Case Discussion and Q&A
TBD
Fellow / Junior Faculty
Session VI: Management of Initial Relapse: Part 1
Moderated by:
NM
Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA
10:50 AM
When Should We Start Treatment for Relapse?
JK
Jonathan Kaufman, MD
Emory Winship Cancer Institute, Atlanta, GA
11:05 AM
Treatment at First Relapse – IMiD-PI-anti- CD38 Based Combinations Should Be First Choice
Binod Dhakal, MD
Medical College of Wisconsin, Wauwatosa, WI
11:20 AM
CAR-T Should Be the Treatment of Choice
DH
Doris Hansen, MD
Moffitt Cancer Center, FL
Session VII: Management of Initial Relapse: Part 2
Moderated by:
NR
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
01:40 PM
Bispecific Antibody Should Be the Treatment of Choice
Krina Patel, MD
Moffitt Cancer Center, FL
01:55 PM
ADC Should Be the Treatment Choice
ST
Suzanne Trudel, MD
The Princess Margaret Cancer Centre, Toronto, Canada
02:40 PM
Case Discussion and Q&A
TBD
Fellow / Junior Faculty
Session VIII: Management of Late Relapse
Moderated by:
Saad Usmani, MD
Memorial Sloan Kettering Cancer Center, New York, NY
04:00 PM
Novel Approaches to TCE Therapies - Bispecifics and Trispecifics
Andrew Yee, MD
Massachusetts General Hospital, Boston, MA
04:15 PM
Novel CAR-T Cell Approaches
TM
Tom Martin, MD
UCSF Health, San Francisco, CA
04:30 PM
Targeted Therapies in MM - Moving Beyond Immunotherapy
Joshua Richter, MD
Icahn School of Medicine at Mount Sinai, New York, NY
05:15 PM
Case Discussion and Q&A
TBD
Fellow / Junior Faculty
Freya Symons
Project Manager
How long has Freya Symons been in the business?
Freya Symons has been with MD Education since 2025.
About Freya Symons
